A Safety Study in Patients With Chronic Lymphocytic Leukemia

Phase 1/2 Completed 12 enrolled Seagen Inc. Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, dose-escalation study to determine the tolerability, safety profile, and antitumor activity of SGN-40 in patients with CLL. All patients will receive dose escalation during the first two weeks regardless of cohort designation.

Timeline

Start: 2005-07
Primary completion: 2006-10
Completion: 2006-10

Publications

Results Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Feb;51(2):228-35. doi: 10.3109/10428190903440946.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dacetuzumab	Monoclonal antibody	3 mg/kg	Intravenous
Subject	dacetuzumab	Monoclonal antibody	4 mg/kg	Intravenous
Subject	dacetuzumab	Monoclonal antibody	6 mg/kg	Intravenous
Subject	dacetuzumab	Monoclonal antibody	8 mg/kg	Intravenous

A Safety Study in Patients With Chronic Lymphocytic Leukemia

Summary

Timeline

Publications

Drugs

Indications